05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of
musculoskeletal disorders; pharmaceutical preparations for
treating metabolic disorders; pharmaceutical preparations
for use in urology; cardiovascular agents for medical
purposes; pharmaceutical preparations for the treatment of
kidney disorders; pharmaceutical preparations for the
treatment of inflammatory diseases; chemico-pharmaceutical
preparations; pharmaceutical preparations for the treatment
of auto-immune diseases; pain relief medication;
pharmaceutical preparations for the treatment of gout.
7.
METHOD OF PREPARING FINERENONE, INTERMEDIATE COMPOUND OF FINERENONE, AND METHOD OF PREPARING THE INTERMEDIATE COMPOUND
The present invention relates to a method for preparing finerenone, an intermediate compound of finerenone, and a method for preparing same. Finerenone is prepared by using an intermediate compound represented by chemical formula 2a or an intermediate compound represented by chemical formula 3.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for use in urology; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of inflammatory diseases; chemico-pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pain relief medication; pharmaceutical preparations for the treatment of gout.
The present invention relates to a method for preparing 4-aminoindan and a method for preparing a dihydroindenyl-pyrazolo[3,4-b]pyridine-amine compound, in which the method for preparing 4-aminoindan comprises the steps of: (Sa) preparing at least one of compound 2a and compound 2b using compound 1; and (Sb) preparing 4-aminoindan using at least one of compound 2a and compound 2b.
C07C 209/36 - Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings
C07C 211/57 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
C07C 205/06 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
C07C 205/49 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
The present invention relates to a method of preparing 4-aminoindan and a method of preparing a dihydroindenyl-pyrazolo[3,4-b]pyridine-amine compound, wherein the method of preparing 4-aminoindan comprises the steps of: (Sa) using compound 1 to prepare compound 2; and (Sb) using compound 2 to prepare 4-aminoindan.
C07C 209/36 - Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings
C07C 211/57 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
C07C 205/06 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
C07C 205/56 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hemisuccinate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
The present invention relates to a novel pharmaceutical composition with improved stability comprising rabeprazole, a pharmaceutically acceptable salt, or hydrates thereof, and a method for producing same. The pharmaceutical composition, according to the present invention, comprising rabeprazole and a pharmaceutically acceptable salt thereof as active ingredients shows excellent stability in gastric fluid with low pH, and can minimize side effects.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Proposed is an incubator that comprises a body including a bottom plate to lay a baby on an upper portion, a fixed frame connected at a lower portion to a side of the body, an elevation frame connected to the fixed frame and configured to be moved up and down with respect to the fixed frame, a heater configured in conjunction with movement of the elevation frame and being moved up and down with up-down movement of the elevation frame, a hood connected to the elevation frame and configured to open and close a top of the body by moving up and down in conjunction with movement of the elevation frame, and a driving mechanism for moving up and down the elevation frame and the hood, and further comprises a tilting means of tilting the heater at a predetermined angle in conjunction with up-down movement of the elevation frame.
A novel polymorphof 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hydrogen sulfate monohydrate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
27.
A PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS
A novel process for preparation of crystalline forms and novel crystalline forms of 1-(8- bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine salts is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
28.
NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE MONO SUCCINATE
Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine mono succinate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
The present invention relates to an incubator comprising: a main body part which has a space formed therein for accommodating an infant; supports of which the lower portions are connected to one side of the main body part; a hood driving part provided with one or more multi joint link units and pivotably coupled to the supports; a hood which is disposed above the main body part, and opens and closes the main body part by means of the operation of the hood driving part; and a heater which is mounted to the hood driving part and changes position so that a heat radiating part faces away from the main body part when the main body part is closed, and faces the main body part when the main body part is open. Thus, the present invention can be easily converted for use as a warmer.
A novel crystalline formof 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine hemisuccinate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
A novel polymorph of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine hydrogen sulfate monohydrate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
A novel polymorph of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N- methylazetidin-3-amine hydrogen sulfate monohydrate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
The present invention relates to a novel heterocycle derivative, a salt thereof, or an isomer thereof. More specifically, the present invention relates to a novel heterocycle derivative effective for the therapy for hair loss such as androgenic alopecia and alopecia areata and having an excellent preventive effect of hair loss, a salt or isomer thereof, and a composition comprising same as an effective ingredient for prevention of hair loss.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
The present invention relates to a therapeutic composition, comprising a compound having excellent therapeutic efficacy for pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) or pulmonary fibrosis caused by coronavirus disease-19 infection.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
40.
COMPOSITION FOR TREATING CORONAVIRUS DISEASE-19 (COVID-19)
The present invention relates to a treatment composition comprising a compound capable of very specifically and highly efficiently inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2).
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention relates to a novel heterocycle derivative, a salt thereof, or an isomer thereof. More specifically, the present invention relates to a novel heterocycle derivative effective for the therapy for hair loss such as androgenic alopecia and alopecia areata and having an excellent preventive effect of hair loss, a salt or isomer thereof, and a composition comprising same as an effective ingredient for prevention of hair loss.
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A61Q 7/00 - Preparations for affecting hair growth
The present invention relates to a novel heterocycle derivative, a salt thereof, or an isomer thereof. More specifically, the present invention relates to a novel heterocycle derivative effective for the therapy of hair loss such as androgenic alopecia and alopecia areata and having an excellent preventive effect of hair loss, a salt or isomer thereof, and a composition comprising same as an effective ingredient for prevention of hair loss.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A61Q 7/00 - Preparations for affecting hair growth
44.
METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND
The present invention provides: a self-emulsifying composition comprising, relative to 100 parts by weight of a solid preparation, 0.1-0.5 parts by weight of dutasteride, 6-110 parts by weight of oil, and 6-110 parts by weight of a surfactant; a solid preparation comprising 5-185 parts by weight of a coating excipient comprising pores formed in a surface thereof, the self-emulsifying composition being accommodated in the pores; and a method for preparing the solid preparation.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
The present invention relates to a method for preparing a heterocyclic derivative compound of chemical fonnula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid- related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I, wherein formula I is
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
C07C 309/05 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
49.
Crystal of doripenem, and preparation method therefor
This invention relates to a novel doripenem crystal, a solvate thereof, and a preparation method thereof and, more specifically, to a novel doripenem anhydride crystal, a method of preparing the doripenem anhydride crystal using various solvents, and a solvate of doripenem.
C07D 477/10 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
C07D 477/12 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
50.
NOVEL DESFESOTERODINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
The present invention relates to a novel desfesoterodine derivative or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a novel desfesoterodine derivative or a pharmaceutically acceptable salt thereof, which is biostable and is effective in the treatment of overactive bladder symptoms such as urinary incontinence, urinary urgency and urinary frequency, and a pharmaceutical composition comprising same for prevention and treatment of overactive bladder symptoms such as urinary incontinence, urinary urgency and urinary frequency.
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
51.
PHARMACEUTICAL COMPOSITION COMPRISING PITAVASTATIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND VALSARTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Disclosed is a composite composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof and the composite pharmaceutical composition is more stable than simple formulations in combination, and is economically beneficial compared to a controlled-release formulation.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
54.
NOVEL CRYSTAL OF DORIPENEM, AND PREPARATION METHOD THEREFOR
The present invention relates to a novel crystal of doripenem, a solvate thereof, and a preparation method therefor. More specifically, the novel crystal is an anhydrous crystal of doripenem, and the present invention relates to a method for preparing the anhydrous crystal of doripenem by using various solvents in order to prepare the same, and a solvate of doripenem.
C07D 477/12 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
C07D 477/10 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Acetaminophen for relief of pain; Cough treatment preparations; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of respiratory organs
56.
METHOD FOR PREPARING CRYSTALLINE MEROPENEM TRIHYDRATE
The present invention provides a method for preparing crystalline meropenem trihydrate of formula 1 by crystallization through the hydrogenation of bis-meropenem of formula 2 in a mixed liquid of tetrahydrofuran and water, without a buffer solution but simply by controlling the pH using a base; and a preparation method comprising optimal reaction conditions for preparing meropenem comprising the same. The preparation method for meropenem trihydrate according to the present invention has an advantage of being able to prepare crystalline meropenem hydrate in high purity and high yield using only a simple after-treatment process. In addition, the present invention has an advantage of being able to prepare meropenem trihydrate in which the amount of residual organic solvents, especially acetone, is markedly reduced, unlike the meropenem trihydrate prepared by the preparation method according to the prior art.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
The present invention relates to a method for preparing carbapenem antibiotics, which is capable of preparing carbapenem antibiotics by deprotecting the protective group introduced into carboxy group or amino group with high efficiency and yield rate. The method for preparing carbapenem antibiotics comprises a step of deprotecting, in the presence of transition metal and acid, the carbapenem intermediate compound protected by the protective group having a benzene ring in which one or more carboxy groups or amino groups are substituted.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
59.
Compound of a reverse-turn mimetic and a production method and use therefor
This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method of preparing the same, and the use thereof to treat diseases such as cancer, in particular, acute myeloid leukemia.
A01N 43/64 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
60.
3,6-DISUBSTITUTED INDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITING ACTIVITY
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (Republic of Korea)
Inventor
Jung, Kyung Yun
Choi, Jin Seok
Kim, Min Kyoung
Park, Young Min
Sim, Tae Bo
Roh, Eun Joo
Chin, Sei Ho
Lee, Yong Sil
Kim, Sun Mi
Abstract
The present invention relates to a novel 3,6-disubstituted indazole derivative or a pharmaceutically acceptable salt thereof, to a production method for same, and to a pharmaceutical composition comprising same as an active ingredient. The pharmaceutical composition of the present invention exhibits an outstanding suppressing effect against protein kinases that induce cancer, such as B-Raf kinase, and can therefore be used to advantage in the prevention or treatment of cancer.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
Provided in the present invention is a composition comprising: pyrazino-triazine derivatives; and pharmaceutically acceptable salts thereof. The composition comprises: a solubilizing agent; or a stabilizer, and has significantly superior solubility and stability.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 9/00 - Drugs for disorders of the cardiovascular system
62.
COMPOSITION FOR PREVENTING AND TREATING NON-SMALL CELL LUNG CANCER, CONTAINING PYRAZINO-TRIAZINE DERIVATIVES
The present invention relates to a composition which contains pyrazino-triazine derivatives, isomers thereof, or pharmaceutically acceptable salts thereof. The composition has superior effects in the prevention and treatment of non-small cell lung cancer (NSCLC).
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Provided are: a dry syrup comprising a pharmaceutically active substance, starch and a thixotropic thickener; and a production method therefor. The dry syrup composition is advantageous in that it is rapidly hydrated and changes to an appropriate viscosity range when brought into contact with water, and so weighing and/or dosing convenience is improved and gelatinized starch is broken down inside the mouth such that viscosity is reduced and an easy-to-swallow formulation is possible.
The present invention relates to a novel compound of a reverse-turn mimetic, having pyrazino-triazinone for its basic structure, and to a production method therefor, and the invention relates to use of the compound as a therapeutic agent for diseases having an anticancer effect or the like and, in particular, as a therapeutic agent for acute myeloid leukaemia.
The present invention relates to oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, to a pharmaceutical composition comprising the nanoparticles, and to a method which involves emulsifying a lipid mixture solution, in which solid lipids and a surfactant are mixed, into an aqueous mixture solution in which oxaliplatin and a specific cosolvent are mixed, and removing the solid lipids and the cosolvent using supercritical fluid gas, to thereby prepare orally administrable nanoscale oxaliplatin particles. The oxaliplatin nanoparticles and method for preparing same according to the present invention are advantageous in that oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, can be prepared in an economic manner using a supercritical fluid production facility which is relatively inexpensive, and oxaliplatin nanoparticles can be prepared with a high recovery factor through a simple process and can be easily commercialized. In addition, oxaliplatin, which has been thus-far prepared as injectable formulations, is prepared into nanoparticles to enable the development of oxaliplatin oral formulations which are safe to stomach acids and which have improved bioavailability, thereby preventing inconveniences and problems in using injectable formulations, and significantly contributing to the improvement of patient compliance and a reduction in medical expenses.
Disclosed are novel reverse turn mimetics based on the framework of pyrazino-triazinone, and the use thereof in the treatment of cancers, particularly, acute myeloid leukemia. A method is also provided for manufacturing the reverse turn mimetics on a mass scale.
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
67.
NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF
Disclosed are novel reverse turn mimetics based on the framework of pyrazino-triazinone, and the use thereof in the treatment of cancers, particularly, acute myeloid leukemia. A method is also provided for manufacturing the reverse turn mimetics on a mass scale.
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
68.
METHOD FOR PREPARING DENDRITIC CELLS WITH CAPACITY TO INDUCE CANCER-SPECIFIC IMMUNE RESPONSE, AND PHARMACEUTICAL COMPOSITION AND KIT INCORPORATING DENDRITIC CELLS FOR PREVENTING OR TREATING CANCER OR INHIBITING METASTASIS
The present invention relates to a method for preparing mature dendritic cells, having a significantly improved capacity for inducing a cancer-specific immune response; a pharmaceutical composition for preventing or treating a cancer or inhibiting cancer metastasis, containing the mature dendritic cells prepared by using the above method; and a pharmaceutical kit incorporating the mature dendritic cells and an imiquimod prepared by the above method. Accordingly, it is possible to prepare safe mature dendritic cells which significantly improves the induction capacity of the cancer-specific immune response and lowers toxicity. The mature dendritic cells are effective in preventing and treating cancer, and inhibiting metastasis. In parallel with administering the cancer-specific mature dendritic cells, the imiquimod used for preparing the pharmaceutical kit improves cancer immunotherapy and prevents or treats a cancer and inhibits cancer metastasis.
The present invention relates to an interferon-α (IFN-α) fused protein, comprising IFN-α fused to cytoplasmic transduction peptide (CTP). Specifically, the present invention relates to a fused protein wherein a CTP, which binds cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-α, thereby enhancing the conjugation capacity of cell membranes and antivirus activity; inhibiting CTP transport into the cell nucleus; enhancing the translocation and settlement of the fused protein into the liver and of transduction to liver tissue. Accordingly, it is possible to develop medical products from the fused protein which are effective at low doses for preventing or treating liver diseases associated with viral infection.
